A comparative study of Parkinson's disease and leucine-rich repeat kinase 2 p.G2019S parkinsonism

Joanne Trinh*, Rim Amouri, John E. Duda, James F. Morley, Matthew Read, Alan Donald, Carles Vilariño-Güell, Christina Thompson, Chelsea Szu Tu, Emil K. Gustavsson, Samia Ben Sassi, Emna Hentati, Mourad Zouari, Emna Farhat, Fatma Nabli, Faycel Hentati, Matthew J. Farrer

*Corresponding author for this work
56 Citations (Scopus)


Parkinson disease is a progressive neurodegenerative disease for which leucine-rich repeat kinase 2 (LRRK2 carriers) p.G2019S confers substantial genotypic and population attributable risk. With informed consent, we have recruited clinical data from 778 patients from Tunisia (of which 266 have LRRK2 parkinsonism) and 580 unaffected subjects. Motor, autonomic, and cognitive assessments in idiopathic Parkinson disease and LRRK2 patients were compared with regression models. The age-associated cumulative incidence of LRRK2 parkinsonism was also estimated using case-control and family-based designs. LRRK2 parkinsonism patients had slightly less gastrointestinal dysfunction and rapid eye movement sleep disorder. Overall, disease penetrance in LRRK2 carriers was 80% by 70 years but women become affected a median 5 years younger than men. Idiopathic Parkinson disease patients with younger age at diagnosis have slower disease progression. However, age at diagnoses does not predict progression in LRRK2 parkinsonism. LRRK2 p.G2019S mutation is a useful aid to diagnosis and modifiers of disease in LRRK2 parkinsonism may aid in developing therapeutic targets.

Original languageEnglish
JournalNeurobiology of Aging
Issue number5
Pages (from-to)1125-1131
Number of pages7
Publication statusPublished - 05.2014


Dive into the research topics of 'A comparative study of Parkinson's disease and leucine-rich repeat kinase 2 p.G2019S parkinsonism'. Together they form a unique fingerprint.

Cite this